These medications particularly benefit patients with a BMI of 30 or more, who face four to five times higher risk of heart disease, stroke, and diabetes 2
7.4 Catestatin and autonomicmetabolic regulation Catestatin, a peptide derived from the prohormone chromogranin A, inhibits catecholamine release and modulates sympathetic tone
At this time, they should not replace proven treatments but may have a role in carefully selected, closely monitored patients
The clinical data is overwhelming
Significant overdose, particularly when used with insulin or sulfonylureas, could potentially lead to hypoglycemia
The end of the survey suggested a treatment plan and offered a choice between 3-, 6-, and 12-month supplies